6 September 2022 (Tuesday) - Transfusion News Update

The Transfusion News email came in today… I was rather surprised to read the last article about artificial blood… I can remember being told that artificial blood (as in something that carries oxygen and carbon dioxide about) was ready for commercial production in 1981…

Mitapivat Trial Results in Adults with Pyruvate Kinase Deficiency Requiring Transfusions

Transfusion News Image 1
August 31, 2022
Pyruvate kinase deficiency is a rare, congenital form of chronic hemolytic anemia. Current treatments for pyruvate kinase deficiency, including RBC transfusions and splenectomy, are supportive only and do not address the metabolic defect of the disease. Mitapivat, however, is the first of a new class of oral drugs that activates pyruvate kinase, the enzyme in the RBC responsible for catalyzing the last step of glycolysis and producing ATP necessary to maintain RBC health. [Read More]
Join us to hear about existing strategies to either prevent, or diagnose and treat HDFN
Transfusion News Image 1
In this new Transfusion Science Webinar, Carla Dinardo, MD, PhD, explains why the Hemolytic Disease of the Fetus and Newborn remains a challenge despite the many advances made to either prevent, or diagnose and treat HDFN and its complications. [Register Now]
Results from Phase 1 Trial for Artificial Hemoglobin Vesicles
Transfusion News Image 1
August 24, 2022
Advantages of artificial red blood cells (RBCs) include reduced risks of pathogens and alloimmunization and greater storage time compared to standard RBCs. Several artificial RBCs have been developed; however, they have been associated with higher risks of myocardial infarction and death in clinical trials. [Read More]


No comments:

Post a Comment